A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

Exclusion Criteria

• •Has a seated SBP ≥ 180 mmHg or DBP ≥ 110 mmHg;
• •Has a body mass index (BMI) \> 40 kg/m2;
• •Has an upper arm circumference \< 7 or \> 17 inches;
• •Has been on night shifts at any time during the 4 weeks before Screening;
• •Is using a beta blocker for any primary indication other than systemic hypertension (eg, migraine headache);
• •Is not willing or not able to discontinue an MRA or a potassium sparing diuretic as part of an existing antihypertensive regimen;
• •Is not willing or not able to discontinue taking a potassium supplement;
• •Has documented estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73m2
• •Has known and documented New York Heart Association stage III or IV chronic heart failure
• •Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before Screening;
• •Has known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease diagnosed from a prior echocardiogram;
• •Major cardiac surgery (eg, CABG, valve replacement), peripheral arterial bypass surgery, or PCI within 6 months before Screening;
• •Has chronic permanent atrial fibrillation;
• •Has uncontrolled diabetes with glycosylated hemoglobin \> 9.5% at Screening;
• •Has planned dialysis or kidney transplant during the course of this study;
• •Potassium \< 3.5 mEq/L;
• •Potassium \> 5.0 mEq/L;
• •Is positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen;
• •Has typical consumption of ≥14 alcoholic drinks weekly.